From bench to bedside: Navigating the continuum of cancer research and testing with comprehensive oncology solutions
Deciphering the enormous diversity in genetic abnormalities associated with cancers can help shape our overall understanding of disease progression and treatment. Highly sensitive oncology solutions that can accurately pinpoint the genetic changes that initiate cancer are a crucial requirement for cancer labs. Yet cancer evolves, relentlessly challenging researchers and clinicians, and creating a need for continuous innovation and collaboration for improved patient outcomes – from early detection to personalized treatment.
We can help you in your quest to decode cancer. From unraveling the dynamic tumor microenvironment to identifying and developing the next biomarker for future clinical use, partner with us and benefit from our expertise. Our streamlined Sample to Insight workflows and dedicated technologies can help you overcome the obstacles you face in cancer research and oncology testing. Let’s redefine what’s possible – together.
Explore our comprehensive oncology solutions. Click on the workflow to learn more.
Research workflows
Applications
Tools
Biomarker detection
Signatures
Indications
Diagnostic testing
Latest news and highlights
Success stories
Stars of cancer research
Get up close and personal with star cancer researchers from around the world. Read about their experiences, thoughts and visions.Consortia and initiatives – we're working together
QIAGEN participates in numerous renowned international consortia, grant projects and initiatives that strive to improve global healthcare. They extend and access networks and infrastructures – and stimulate exchange between all relevant stakeholders – from science, medicine and government. Our active role in consortia and initiatives keeps QIAGEN at the forefront of scientific findings and developments.
- European Liquid Biopsy Society (ELBS)
- SPIDIA4P – better diagnosis and medical research
- CBmed – biomarker identification, validation and research
- Instand-NGS4P – integrated and standardized workflows for personalised therapy
- CD Labor – for liquid biopsies for the early diagnostics of cancer
- ColoMark – identification and development of colorectal cancer biomarkers via liquid biopsy
- ISIDORe – enhancing Europe’s capacity for controlling (re)emerging and epidemic infectious diseases
-
Austrian Centre of Industrial Biotechnology (acib) – approaches for early diagnosis based on liquid biopsy markers